Clarifying the role of rasburicase in tumor lysis syndrome (Q36693863)

15 August 2017

1 reference

title

Clarifying the role of rasburicase in tumor lysis syndrome (English)

1 reference

15 August 2017

Amy R Sood

1

1 reference

15 August 2017

Lisa D Burry

series ordinal

2

1 reference

15 August 2017

Doret K F Cheng

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

27

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

111-121

1 reference

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Rasburicase for the treatment and prevention of hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Tumour lysis syndrome: new therapeutic strategies and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Renal tubular damage in rasburicase: risks of alkalinisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Hemolysis and methemoglobinemia secondary to rasburicase administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Advances in the management of malignancy-associated hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Treatment of impending tumor lysis with single-dose rasburicase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Use of single-dose rasburicase in an obese female

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.111

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.1.111

1 reference

15 August 2017

1 reference